You are here

PCI Biotech initiates research collaboration with Bavarian Nordic

Exploring synergies between proprietary technologies to further enhance the effect of novel therapeutic applications in cancer and infectious diseases

Oslo (Norway) 20 August 2018 — PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that it is initiating a preclinical research collaboration with Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) Kvistgaard, Denmark, a clinical stage biopharmaceutical corporation focused on developing state-of-the-art cancer immunotherapies and vaccines for infectious diseases.

In brief, the collaborators will evaluate technology compatibility and synergy based on in vivo studies. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership.

Per Walday, CEO of PCI Biotech, said: “I’m very pleased to announce another research agreement with a key player within the field of immunotherapies, which is the second collaboration initiated this year. We believe that the PCI technology has the potential to play a role in the realisation of several new therapeutic modalities, and we look forward to explore synergies with Bavarian Nordic’s unique and innovative technologies.“

Contact information:                 
Per Walday, CEO
pw@pcibiotech.no
Mobile: +47 917 93 429

About PCI Biotech          
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaChem programme consists of a clinical Phase I/II study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com    
 
Forward-looking statements  
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Monday, August 20, 2018 - 03:00